TibaRay has launched a Regulation CF campaign on Wefunder, opening its investment opportunity to individual investors as the company advances its next-generation accelerator technology designed to enable FLASH radiotherapy. The campaign marks a significant step for the Fremont, California-based company, which was spun out from Stanford University and has already secured over $27 million in development funding, including more than $14 million in non-dilutive federal research grants.
FLASH radiotherapy delivers radiation doses hundreds of times faster than conventional systems. Research suggests this ultrafast delivery may reduce damage to healthy tissue while maintaining tumor control, potentially transforming cancer treatment. However, enabling this approach requires fundamentally new accelerator technology, which TibaRay is developing.
The company's proprietary Galactica linear accelerator has already been integrated into Leo Cancer Care's upright radiotherapy system, marking TibaRay's first commercial deployment. This integration demonstrates the platform's viability and paves the way for broader adoption. TibaRay's intellectual property portfolio includes more than 20 issued and pending patents related to next-generation radiotherapy systems.
The company is pursuing a phased commercialization strategy. In the near term, it generates revenue by commercializing its accelerator technology across medical and adjacent markets, including imaging, security scanning, and non-destructive testing. The long-term objective is deployment of the PHASER radiotherapy system, designed to enable ultrafast treatment delivery.
The Wefunder campaign allows individual investors to participate in this next phase of development. Investors can review the full opportunity, including technology details, partnerships, and development plans on the TibaRay campaign page. The campaign falls under Regulation Crowdfunding (CF), enabling non-accredited investors to contribute.
For more information, the original press release is available on NewMediaWire.
